Influence of the Infectious Dose of Simian Immunodeficiency Virus on the Acute Infection in Cynomolgus Monkeys and on the Effect of Treatment with 3′-Fluorothymidine
Free accessResearch articleFirst published online October, 1992
Influence of the Infectious Dose of Simian Immunodeficiency Virus on the Acute Infection in Cynomolgus Monkeys and on the Effect of Treatment with 3′-Fluorothymidine
Inoculation of cynomolgus monkeys with simian immunodeficiency virus (SIVSM) results in an acute infection with circulating viral antigen. The time for appearance of the viral antigen peak was dependent on the dose of virus given, a reduced dose of virus resulting in a later peak. 3′-Fluorothymidine (FLT) was given at a dose of 3 × 5mg kg−1 day−1 starting 8 h before virus inoculation and then every 8 h for 10 days. In monkeys inoculated with 500–2500 infectious doses of SIVSM no significant effect of treatment with FLT was seen. When the amount of virus was reduced to 100 infectious doses or less, treatment with FLT resulted in a significant delay in the appearance of viral antigen. At an inoculum of 2–10 infectious doses per monkey, FLT treatment showed a prophylactic effect.
References
1.
BalzariniJ.BabaM.PauwelsR.HerdewijnP., and DeClercqE. (1988) Anti-retrovirus activity of 3′-fluoro- and 3′-azido-sub-stituted pyrimidine 2′,3′-dideoxynucleoside analogues. Biochem Pharmacol37: 2847–2856.
2.
BazinH.ChattopadhyayaJ.DatemaR.EricsonA.-C.GilljamG.JohanssonN.G.HansenJ.KoshidaR.MoellingK.ÖbergB.RemaudG.SteningVrangL.WahrenB., and WuJ.C. (1989) An analysis of replication of HIV and MuLV by some 3′-blocked pyrimidine analogs. Biochem Pharmacol38: 109–119.
3.
BuckheitR.W., and SwanstromR. (1991) Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity. AIDS Res Hum Retroviruses7: 295–302.
4.
DanielM.D.LetvinN.L.SehgalP.K.HunsmannG.SchmidtD.K.KingN.W., and DesrosiersR.C. (1987) Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. J Gen Virol68: 3183–3189.
5.
FieldH.J.BellS.E.ElionG.B.NashA.A., and WildyP. (1979) Effect of acycloguanosine treatment on acute and latent herpes simplex infections in mice. Antimicrob Agents Chemother15: 554–561.
6.
FultzP.N.McClureH.M.AndersonD.C.SwensonR.B.AnandR., and SrinivasanA. (1986) Isolation of T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys). Proc Natl Acad Sci USA83: 5286–5290.
7.
GardnerM.B., and LuciwP.A. (1989) Animal models of AIDS. FASEB J3: 2593–2606.
8.
GrunertR.R., and HoffmannC.E. (1977) Sensitivity of influenza A/New Jersey/8/76 (Hsw 1N1) virus to amantadine HCl. J Infect Dis136: 297–300.
9.
HarmenbergJ.WahrenB., and ÖbergB. (1980) Influence of cells and virus multiplicity on the inhibition of herpesviruses with acycloguanosine. Intervirology14, 239–244.
10.
HartmannH.VogtM.W.DurnoA.G.HirschM.S.HunsmannG., and EcksteinF. (1988) Enhanced in vitro inhibition of HIV-1 replication by 3′-fluoro-3′-deoxythymidine compared to several other nucleoside analogs. AIDS Res Hum Retroviruses4: 457–466.
11.
HendersonD.K., and GerberdingJ.L. (1989) Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: an interim analysis. J Infect Dis160: 321–327.
12.
HerdewijnP.BalzariniP.De ClercqE.PauwelsR.BabaM.BroderS., and VanderhaegheH. (1987) 3′-Substituted 2′,3′-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents. J Med Chem30: 1270–1278.
13.
HoD.D.MoudgilT., and AlamM. (1989) Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med321: 1621–1625.
14.
JacksonG.G. (1975) A perspective from controlled investigations on chemotherapy for viral respiratory infections. J Infect Dis133Suppl: 82–92.
15.
KoshidaR.CoxS.HarmenbergJ.GilljamG., and WahrenB. (1989) Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combinations with phosphonoformate against human immunodeficiency virus type I. Antimicrob Agents Chemother33: 2083–2088.
16.
LangG.NarayanO., and RouseB.T. (1970) Prevention of malignant avian influenza by 1-adamantanamine hydrochloride. Arch Ges Virusforsch32: 171–184.
17.
LangeJ.M.A.BoucherC.A.B.HollakC.E.M.WiltinkE.H.H.ReissP.van RoyenE.A.RoosM.DannerS.A., and GoudsmitJ. (1990) Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med322: 1375–1377.
18.
LundgrenB.Ljungdahl-StåhleE.BöttigerD.BenthinR.HedströmK.G.NorrbyE.PutkonehP.WahrenB., and ÖbergB. (1990) Acute infection of cynomolgus monkeys with simian immunodeficiency virus (SIVSM) as a model to evaluate antiviral compounds. Effects of 3′-azido, 3′-deoxythymidine, foscamet and 2′,3′-dideoxycytidine. Antiviral Chem Chemother1: 299–306.
19.
LundgrenB.BöttigerD.Ljungdahl-StåhleE.NorrbyE.StahleL.WahrenB., and ÖbergB. (1991) Antiviral effects of 3′-fluorothymidine and 3′-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J AIDS4: 489–498.
20.
MatthesE.LehmannC.ScholzD.RosenthalH.A., and LangenP. (1988) Phosphorylation, anti-HIV activity and cytotoxicity of 3′-fluorothymidine. Biochem Biophys Res Comm153: 825–831.
21.
McClureH.M.AndersonD.C.FultzP.N.AnsariA.A.LockwoodE., and BrodieA. (1989) Spectrum of disease in macaque monkeys chronically infected with SIVSMM. Vet Immunol Immunopath21: 13–24.
22.
McClureH.D.AndersonD.C.AnsariA.A.FultzP.KlumppS.A., and SchinaziR.F. (1990) Nonhuman primate models for evaluation of AIDS therapy. In: AIDS. Anti-HIVagents, therapies and vaccines. St. GeorgievV., and McGowanJ.J. (eds). Ann NY Acad Sci 616: 287–298.
23.
PutkonenP.WarstedtK.ThorstenssonR.BenthinR.AlbertJ.LundgrenB.ÖbergB.NorrbyE., and BiberfeldG. (1989) Experimental infection of cynomolgus monkeys (Macaca fascicularis) with simian immunodeficiency virus. J AIDS2: 359–365.
24.
PutkonenP.ThorstenssonR.BenthinR.HedströmK.-G.ÖbergB.NorrbyE., and BiberfeldG. (1990) Animal models for HIV infection and AIDS: HIV-2 and SIVSM infections of cynomolgus monkeys. In: AIDS. SchellekensH.HorzinekM.C. (eds). Amsterdam: Elsevier/North Holland and Biomedical Press, pp. 81–85.
25.
SchinaziR.F. (1987) Drug combinations for treatment of mice infected with acyclovir-resistant herpes simplex virus. Antimicrob Agents Chemother31: 477–479.
26.
TsaiC.-C.FollisK.E.YarnallM.DeaverL.E.BenvenisteR.E., and SagerP.R. (1990) In vitro screening for antiretroviral agents against simian immunodeficiency virus (SIV). Antiviral Res14: 87–90.
27.
VrangL.ÖbergB.LöwerJ., and KurthR. (1988) Reverse transcriptases from human immunodeficiency virus type 1 (HIV-1), HIV-2 and simian immunodeficiency virus (SIVMAC) are susceptible to inhibition by foscamet and 3′-azido-3′-deoxythymidine triphosphate. Antimicrob Agents Chemother32: 1733–1734.
28.
ZakO., and O'ReillyT. (1990) Animal models as predictors of the safety and efficacy of antibiotics. Eur J Clin Microbiol Infect Dis9: 472–478.
